News

Thimerosal in Vaccine Not Seen as Risky for Infants


 

The findings support results from recent studies, including a study conducted by the Centers for Disease Control and Prevention that showed no association between exposure to ethyl mercury from thimerosal-containing vaccines during infancy and neuropsychological outcomes at age 7–10 years (N. Engl. J. Med. 2007;357:1281–92).

Additionally, a population-based study that was conducted in California last year showed an increase in the prevalence of autism in the years since thimerosal-containing vaccines were discontinued (Arch. Gen. Psychiatry 2008;65:19–24).

The blood half-life of mercury after administration was estimated to be 3.7 days, and did not vary by age group. DR. PICHICHERO

Pages

Recommended Reading

Optic Neuritis After Varicella Often Resolves Spontaneously
MDedge Neurology
FYI
MDedge Neurology
In Neonates, CNS Herpes Diagnosis Can Prove Challenging
MDedge Neurology
Coiling Is Effective for Pediatric Brain Aneurysms : Other treatments that have stood the test of time are clipping, embolization, and/or surgery.
MDedge Neurology
FDA Approves FluMist for Use in Children Aged 2–5 Years
MDedge Neurology
Image of the Month
MDedge Neurology
Data Watch: Cerebral Palsy Birth Prevalence Dropped In Very-Low-Birth-Weight* Infants in Europe
MDedge Neurology
Image of the Month
MDedge Neurology
C. immitis Meningitis Can Present Without Hydrocephalus
MDedge Neurology
Large Pilocytic Astrocytoma May Be Aggressive
MDedge Neurology